WuXi Biologics Statement

This has no impact on our business or ongoing services to global partners. There is very minimal impact to our imports as no such equipment is required after facility construction in Shanghai and Wuxi. We welcome inspection at any time for the clearance and removal from such list.  We are also pursuing interim measures to remove these subsidiaries from the list prior to inspection. This has no impact on our business or ongoing services to global partners. There is very minimal impact to our...

SHANGHAI, 08/02/2022 (informazione.news - comunicati stampa - scienza e tecnologia)

This has no impact on our business or ongoing services to global partners. There is very minimal impact to our imports as no such equipment is required after facility construction in Shanghai and Wuxi. We welcome inspection at any time for the clearance and removal from such list.  We are also pursuing interim measures to remove these subsidiaries from the list prior to inspection.

WuXi Biologics (stock code: 2269.HK), a Hong Kong -listed company, is a leading global biologics Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that empower partners to discover, develop and manufacture biologics from concept to commercial manufacturing for the benefit of patients worldwide. For more information about WuXi Biologics, please visit: www.wuxibiologics.com.   

Media
PR@wuxibiologics.com 

Investors
IR@wuxibiologics.com